HBM Holdings Limited (HKG:2142)

Market Cap	6.33B
Revenue (ttm)	295.94M
Net Income (ttm)	21.58M
Shares Out	795.54M
EPS (ttm)	0.03
PE Ratio	283.40
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,510,000
Average Volume	10,269,750
Open	7.90
Previous Close	7.89
Day's Range	7.58 - 8.04
52-Week Range	1.06 - 10.00
Beta	1.74
RSI	43.10
Earnings Date	May 28, 2025

About HBM Holdings

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics in immunology and oncology disease areas. It develops the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody target...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD